Mylan N.V. Slashes Full-Year Outlook Due to Continued U.S. Market Challenges

Various pills on top of $100 bills

Asterisks were needed on several numbers when Mylan N.V. (NASDAQ: MYL) reported its first-quarter results in May. The drugmaker's revenue then was boosted by foreign exchange fluctuations, and its earnings were helped a lot by tax benefits.

By contrast, when Mylan announced its Q2 results before the market opened on Wednesday, fewer caveats were required -- but that wasn't necessarily a good thing.

Mylan results: The raw numbers

Data Source: Mylan.

What happened this quarter?

Mylan operates globally, and in much of the world, it's performing pretty well. Net sales in Europe were up 4% to nearly $991 million. Net sales in all other countries outside of Europe and North America looked even better, with a year-over-year jump of 10% to $764 million.

But North America continued to be a problem area. Net sales in the region of $1 billion were 22% lower than in the prior-year period. Among the issues dragging down revenues were product discontinuations, problems at one of its U.S. manufacturing facilities, and lower prices for many of its products. It also experienced significantly lower sales volumes for its EpiPen auto-injector.

The drugmaker's overall revenue decline trickled down to its bottom line. Gross margin fell partially due to this revenue drop, but also from costs associated with product acquisitions, and expenses related to the resolution of issues at its Morgantown, West Virginia, manufacturing facility. Taking an additional bite out of Mylan's GAAP net income was a 14% year-over-year jump in research and development spending, an increase due in part to collaboration agreements.

The year-over-year comparisons on adjusted EPS weren't great, but they weren't nearly as troubling as Mylan's GAAP net income deterioration -- the adjusted earnings excluded a number negative impacts.

However, there was one bright spot for Mylan in the second quarter: Adjusted free cash flow increased nearly 8% year over year to $661.4 million.

What management had to say

Mylan CEO Heather Bresch stated:

Looking forward

The rest of the year is likely to be bleaker than was previously expected. Mylan lowered its 2018 revenue guidance from a $11.75 billion to $13.25 billion range to a $11.25 billion to $12.25 billion range.

The drugmaker projects adjusted EPS for 2018 will be between $4.55 and $4.90. Three months ago, the company was anticipating full-year adjusted EPS between $5.20 and $5.60. The only good news in Mylan's revised guidance is that the company still expects adjusted free cash flow of $2.1 billion to $2.5 billion.

Despite the weaker outlook for the year, Mylan has some positives to look forward to over the longer run. The company recently launched its biosimilar to Amgen 's Neulasta, and prospects for European approval of its Humira biosimilar appear good.

The biggest thing for investors to look forward to, though, relates to an announcement made by Mylan's board of directors on Wednesday morning. In a press release, the board reiterated its confidence in Mylan's future, but also stated that it is "actively evaluating a wide range of alternatives to unlock the true value" of the company's "one-of-a-kind platform." No details were provided about what options they could be considering.

10 stocks we like better than Mylan

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Mylan wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of August 6, 2018

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Amgen and Mylan. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.